Small biopharmaceutical companies are becoming increasingly important as drivers of innovation in drug development. It has recently been estimated that the majority of drugs currently in development are in the hands of small biopharmaceutical companies.1 Such companies range in size…
Is Indian Bioeconomy outgrown the Pharma industry?
ABLE, a biotech industry lobby group formed in 2003, in its report noted that the Indian bioeconomy has crossed $42 billion in 2017 and biotechnology industry is valued at $19 billion. Contrary to this, India Brand Equity Foundation (IBEF), in…
CDSCO puts Wockhardt, two others under scanner for selling drug without clearances
The CDSCO looks to give show case notices along with cancelling their licenses for the offence. These companies were apparently selling combination drugs to treat diabetes and fungal infections without the required approval. The Central Drug Standards Control Organisation (CDSCO)…
2018 and Beyond: Outlook and Turning Points
Global health is poised to meet a series of key turning points, and changes seen in 2018 will mark the key inflections that drive the outlook for the next five years and beyond. The types of medicines being developed, the…
Eliminating Silos: Dismantling the Frankenstein of Clinical R&D
In 2001 there were 1,198 pharmaceutical organizations with a total of 5,995 drugs in the pipeline; as of January 2017, Pharmaprojects reports those numbers rose to 4,003 pharmaceutical companies with nearly 15,000 drugs in the pipeline. Sponsors and trials are…
Clinical Monitor Turnover Rates, Salaries Continue to Climb
Clinical research associates/monitors outside the United States don’t appear to be very happy in their jobs. According to a new “niche” survey from HR+Survey Solutions, international employee turnover in this job category leapt to nearly 23% in 2016. That’s up…
Government puts up National Rare Disease Policy in place; allocates Rs 100 crore towards genetic disorders
Rare diseases, which are often referred to as orphan diseases, are estimated to have impacted 72-96 million people in India. The Indian government has now put a National Rare Disease Policy in place and Rs 100 crore funds have been…
Pain Points for Clinical Trials Sites Abound In Systems And Devices
Clinical trial sponsors often rave about the data they collect from mobile devices, and visionaries wax poetic about the ways these datasets—combined with artificial intelligence and machine learning—will change medicine. But along the way clinical trial sites are drowning in…
